HighTower Advisors
VKTX icon

HighTower Advisors’s Viking Therapeutics VKTX Stock Holding History

HighTower Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$1K – 3493
2021
Q3 		$1K Buy
+2,000
New +$12.4K ﹤0.01% 3153

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighTower Advisors's VKTX Position: Q2 2026 in Review

HighTower Advisors opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 6,096 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #3411 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in VKTX as recently as Q4 2025.

HighTower Advisors first reported a position in VKTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $507K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • HighTower Advisors held 6,096 shares of Viking Therapeutics worth $238K as of Q2 2026.
  • Viking Therapeutics was a new HighTower Advisors position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3411 holding.
  • HighTower Advisors first reported a position in Viking Therapeutics in Q3 2018 and has held it in 17 quarters since.
  • HighTower Advisors's Viking Therapeutics position peaked at $507K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.